Loureirin B Alleviates Myocardial Ischemia/Reperfusion Injury via Inhibiting PAI-1/TGF-β1/Smad Signaling Pathway

Figure 1

Loureirin B (LrB) improved cardiac function and reduced infarct size in mice with myocardial ischemia/reperfusion (MI/R). Mice were subjected to MI/R and treated with 0.5 mg/kg LrB or 1 mg/kg LrB per day for 4 weeks. Four weeks later, cardiac function of the mice was measured, and the cardiac tissues were harvested for further examination. (a) Left ventricular end-diastolic diameter (LVEDD), (b) left ventricular end-systolic diameter (LVESD), (c) left ventricular fractional shortening (LVFS), and (d) left ventricular ejection fraction (LVEF) measured by echocardiographic examination. (e) The ratio of heart weight (HW) to body weight (BW). (f) Representative photographs of heart cross sections after TTC staining. (g) The percentage of myocardial infarct area. Values are expressed as mean ± SD (n = 6). , vs. sham group. , , vs. MI/R group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)